INTRODUCTION {#s1}
============

Non-coding RNAs (ncRNAs) encoded by the eukaryotic genome are considered as a large number of RNAs which are not translated into proteins. Indeed, more than 90% of noncoding RNAs used to be recognized as "biological noises" in transcription progression compared with about 3% protein-coding genes until the development of high-throughput sequencing technology and large-scale mapping of transcriptomes \[[@R1], [@R2]\]. Based on structural features and biological functions, ncRNAs family has been further classified into housekeeping and regulatory ncRNAs. Regulatory ncRNAs upon nucleotide length are generally divided into two subgroups: (1) short ncRNAs shorter than 200 nucleotides such as microRNAs (miRNAs); (2) long noncoding RNAs (lncRNAs) longer than 200 nucleotides such as intergenic lncRNAs (lincRNAs) and circular RNAs (circRNAs) \[[@R3], [@R4]\]. Accumulating evidence have revealed the major transcriptional and post-transcriptional regulation roles of lncRNAs emerge in transcription factor recruitment, chromatin remodeling, histone modification, pre-mRNA splicing, molecular sponge and scaffold, which are involved in development of normal tissue or organ and carcinogenesis and aggression of diverse malignancies \[[@R5]--[@R8]\].

Urothelial cancer associated 1 also known as UCA1 is located on 19p13.12 encodes 3 isoforms (1.4, 2.2 and 2.7 kb) with ployA tails, in which the 2.2 kb isoform is called cancer upregulated drug resistant (CUDR). Previous study has shown UCA1, a highly conserved nuclear-enriched lncRNA, is ubiquitous in different development stages of urinary system, productive system, digestive system and respiratory system \[[@R9]\]. In cancers, UCA1 as an oncogene exhibited regulatory mechanisms responsible for cell proliferation, invasion, metastasis, apoptosis, metabolism and chemoresistance \[[@R10]\]. Cheng et al. reported that downregulation of UCA1 impaired chemoresistance of non-small cell lung cancer cells with non-T790M to gefitinib by inhibition of the AKT/mTOR pathway \[[@R11]\]. Na et al. indicated knockdown of UCA1 inhibited cell proliferation and induced cell apoptosis by inactivation of KLF4-KRT6/13 cascade in prostate cancer \[[@R12]\]. Wang et al. showed that UCA1 as an endogenous sponge restored the negative effect of miR-216b on the growth and metastasis of hepatocellular carcinoma cells through activating FGFR1/ERK signaling pathway \[[@R13]\]. Hu et al. revealed the X protein encoded by HBV increased UCA1 expression which inhibited cell apoptosis and promoted cell proliferation and carcinogenesis by HBx-UCA1/EZH2-p27Kip1 signaling axis in hepatocellular carcinoma cells \[[@R14]\].

Furthermore, increasing interest has been focused on whether UCA1 acts as a diagnosis and prognosis biomarker in cancer detection and treatment. UCA1 was firstly characterized as an effective diagnosis biomarker in bladder cancer with a high sensitivity and specificity (80.9% and 91.8%) \[[@R15]\]. Meanwhile, growing subsequent evidence suggest that aberrant overexpression of UCA1 is associated with high risk of poor outcome or clinicopathological characteristics in breast cancer, colorectal cancer, bladder cancer, esophageal squamous cell carcinoma, epithelial ovarian cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, prostate cancer and tongue squamous cell carcinoma \[[@R11]--[@R13], [@R15]--[@R27]\]. Thus, it is necessary to certificate the potential correlation between UCA1 expression and malignancies by a comprehensive analysis. In this meta-analysis, we qualified and evaluated present studies to explore the association of UCA1 with prognostic and clinicopathological significance in patients with different types of carcinomas.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

Upon an electrical search on PubMed, Embase, Cochrane Library and Web of Science databases, a total of 19 eligible OS papers including 1587 tissue specimens from 1774 records published from 2014 to 2017 were enrolled by a cautious searching strategy and full-text screening, which were based on inclusion and exclusion criteria in this meta-analysis (Figure [1](#F1){ref-type="fig"}). Participants in 19 OS studies were all Asian with 10 types of tumors including non-small cell lung carcinoma (NSCLC), gastric cancer (GC), colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), prostate cancer (PC), hepatocellular cancer (HCC), epithelial ovarian cancer (EOC), endometrial cancer (EC), pancreatic cancer (PAC), and breast cancer (BC) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The main characteristics of retrieved OS studies were summarized in Table [1](#T1){ref-type="table"}. Meanwhile, total 16 available clinicopathological studies containing 1291 tissue samples were collected to analyze the correlation between UCA1 level and clinicopathological data (clinical stage, tumor size, lymphatic and distant metastasis) shown in ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). And all clinicopathological studies were Asian with 8 kinds of tumors above except prostate and breast cancer. Quality evaluation based on reporting recommendations for tumor marker prognostic studies (REMARK) guideline reflected quality score ranged from 40% to 80% in ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}). With inconsistent cut-off values due to different detection methods, the patients were separated into high and low level of UCA1 groups. HRs with 95% CIs were extracted from multivariate analysis in 14 studies, univariate analysis in 5 studies (estimated effects collected from Kaplan--Meier survival curve in 3 studies).

![Workflow of searching strategy and study selection in the meta-analysis](oncotarget-08-28373-g001){#F1}

###### The main characteristics of included OS studies in the prognosis based on meta-analysis

  Study               Year   Region   Tumor type   Sample size   Specimen   Method       Cut-off value         Outcome   Analysis               Quality score (%)
  ------------------- ------ -------- ------------ ------------- ---------- ------------ --------------------- --------- ---------------------- -------------------
  Li, et al.^20^      2014   China    ESCC         90            Tissue     qRT-PCR      Mean (NG)             OS        Multivariable          75
  Zheng, et al.^22^   2015   China    GC           112           Tissue     qRT-PCR      Median (17.24)        OS        Multivariable          75
  Wang, et al.^13^    2015   China    NSCLC        60            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          75
  Ni, et al.^17^      2015   China    CRC          54            Tissue     qRT-PCR      Median (NG)           OS        Univariable analysis   60
  Na, et al.^12^      2015   China    PC           40            Tissue     qRT-PCR      Median (NG)           OS        Univariable            40
  Gao, et al.^23^     2015   China    GC           20            Tissue     qRT-PCR      NG                    OS        Multivariable          40
  Nie, et al.^26^     2015   China    NSCLC        112           Tissue     qRT-PCR      Youden index (NG)     OS        Multivariable          70
  Tao, et al.^43^     2015   China    CRC          80            Tissue     qRT-PCR      Upper quartile (NG)   OS        Multivariable          70
  Wang, et al.^13^    2015   China    HCC          98            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          70
  Yang, et al.^44^    2015   Korea    HCC          240           Tissue     microarray   Median (6.51)         OS        Univariable analysis   50
  Bian, et al.^19^    2016   China    CRC          90            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          70
  Yang, et al.^21^    2016   China    EOC          53            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          75
  Zhang, et al.^45^   2016   China    EOC          117           Tissue     qRT-PCR      Median (NG)           OS        Multivariable          70
  Lu, et al.^46^      2016   China    EC           45            Tissue     qRT-PCR      Median (NG)           OS        Univariable            65
  Shang, et al.^24^   2016   China    GC           77            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          75
  Chen, et al.^47^    2016   China    PAC          128           Tissue     qRT-PCR      Mean (NG)             OS        Multivariable          80
  Fu, et al.^48^      2016   China    PAC          80            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          80
  Liu, et al.^49^     2016   China    BC           54            Tissue     qRT-PCR      Median (NG)           OS        Univariable            45
  Zuo, et al.^50^     2017   China    GC           37            Tissue     qRT-PCR      Median (NG)           OS        Multivariable          75

Abbreviations: ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; NSCLC, non-small cell lung carcinoma; CRC, colorectal cancer; PC, prostate cancer; HCC, hepatocellular cancer; EOC, epithelial ovarian cancer; EC, endometrial cancer; PAC, pancreatic cancer; BC, breast cancer; qRT-PCR, quantitative real-time PCR; OS, overall survival; NG, not given.

Association of UCA1 expression with overall survival in human cancers {#s2_2}
---------------------------------------------------------------------

To assess the association between the UCA1 expression and OS of all cancer patients, a total of 1587 patients with HRs and 95% CIs were included. A significant association was observed between high UCA1 level and poor OS in patients with all 10 types of cancer (pooled HR = 1.85, 95% CI 1.62--2.10, *p* \< 0.001) and no obvious heterogeneity existed across 19 studies under a fixed effect model (I^2^ = 0.0%, p~H~ = 0.905) in Figure [2A](#F2){ref-type="fig"}.

![Prognostic value of UCA1 for OS of cancer patients\
(**A**) Forest plot of HR studies of UCA1 for OS in a fixed effect model. Each study is represented by a square and the center of which denotes the HR with a horizontal 95% Cis lines. The diamond shows the overall HR for combined results. Weights are from a fixed effect analysis. (**B**) Funnel plot for potential publication bias in OS analysis. Standard error (SE) of hazard ratio displays a measure of study size on the vertical axis against hazard ratio on the horizontal axis. (**C**) Egger\'s test for potential publication bias in OS analysis. Standard normal deviate (SND) is defined as the hazard ratio divided by its standard error which is regressed against the estimate\'s precision. (**D**) Sensitivity analysis of the effect of the individual study on the pooled HRs.](oncotarget-08-28373-g002){#F2}

The subgroup analysis in a fixed effect model, random effect model and meta-regression was conducted by cancer types, analysis methods, sample sizes and quality scores for a subsequent investigation of potential heterogeneity in Table [2](#T2){ref-type="table"}. It revealed a significant association between increased UCA1 and OS in patients with GC (pooled HR = 2.32, 95% CI 1.61--3.33, *p* \< 0.001), CRC (pooled HR = 2.16, 95% CI 1.29--3.62, *p* = 0.004), HCC (pooled HR = 1.89, 95% CI 1.20--3.00, *p* = 0.007), and PAC (pooled HR = 1.60, 95% CI 1.16--2.22, *p* = 0.004). There showed no statistical significance of heterogeneity test in subgroups of GC (I^2^ = 0.0%, p~H~ = 0.928), CRC (I^2^ = 0.0%, p~H~ = 0.948), HCC (I^2^ = 0.0%, p~H~ = 0.899), and PAC (I^2^ = 0.0%, p~H~ = 0.457). Then, a significant effect of elevated UCA1 on OS emerged in multivariable analysis subgroup (pooled HR = 1.80, 95% CI 1.55--2.09, *p* \< 0.001) and univariable analysis subgroup (pooled HR = 1.98, 95% CI 1.55--2.55, *p* \< 0.001). No statistically significant heterogeneity was in multivariable analysis subgroup (I^2^ = 0.0%, p~H~ = 0.722) and univariable analysis subgroup (I^2^ = 0.0%, p~H~ = 0.956). Meanwhile, we also detected a significant correlation between overexpression of UCA1 and poor prognosis of cancer patients in large specimen size subgroup (pooled HR = 1.68, 95% CI 1.41--2.00, *p* \< 0.001) and small specimen size subgroup (pooled HR = 2.07, 95% CI 1.71--2.50, *p* \< 0.001) with no evident heterogeneity (I^2^ = 0.0%, p~H~ = 0.639 and I^2^ = 0.0%, p~H~ = 0.979) respectively. To the quality score subgroups, we obtained similar association of upregulation of UCA1 with OS in high quality score subgroup (pooled HR = 1.98, 95% CI 1.58--2.48, *p* \< 0.001) and low quality score subgroup (pooled HR = 1.79, 95% CI 1.53--2.09, *p* \< 0.001). No evidence of significant heterogeneity was found across 2 subgroups (I^2^ = 0.0%, p~H~ = 0.576 and I^2^ = 0.0%, p~H~ = 0.921). Quantified heterogeneous test by meta-regression indicated that no specific factor accounted for the heterogeneity among studies of interest consistent with the outcomes of subgroup analysis in cancer type, analysis method, tumor sample size and quality score covariates.

###### Subgroup and meta-regression analysis of HRs in different cancer type, analysis method, sample size and quality score subgroup

  Subgroup analysis        No. of studies   No. of patients   Pool HR (95% CI)    Meta-regression (*p* value)   Heterogeneity (random)          
  ------------------------ ---------------- ----------------- ------------------- ----------------------------- ------------------------ ------ -------
  Overall survival         19               1587              1.85 (1.62--2.10)   1.85 (1.62--2.10)             \-                       0.0    0.905
  Cancer type                                                                                                                                   
   Digestive system        12               1106              1.97 (1.63--2.38)   1.97 (1.63--2.38)             \-                       0.0    0.963
  GC                       4                246               2.32 (1.61--3.33)   2.32 (1.61--3.33)             0.987                    0.0    0.928
  CRC                      3                224               2.16 (1.29--3.62)   2.16 (1.29--3.62)             0.817                    0.0    0.948
  HCC                      2                338               1.89 (1.20--3.00)   1.89 (1.20--3.00)             0.925                    0.0    0.899
  PAC                      2                208               1.60 (1.16--2.22)   1.60 (1.16--2.22)             0.240                    0.0    0.457
  ESCC                     1                90                2.63 (1.29--5.35)   2.63 (1.29--5.35)             \-                       \-     \-
   Respiratory system      2                172               1.51 (1.16--1.98)   1.51 (1.16--1.98)             \-                       0.0    0.328
  NSCLC                    2                172               1.51 (1.16--1.98)   1.51 (1.16--1.98)             0.454                    0.0    0.328
   Reproductive system     4                269               1.98 (1.57--2.50)   1.98 (1.57--2.50)             \-                       0.0    0.511
  EOC                      2                170               1.88 (1.15--3.09)   2.50 (0.77--8.13)             0.883                    51.2   0.152
  EC                       1                45                2.28 (1.24--4.18)   2.28 (1.24--4.18)             0.961                    \-     \-
  BC                       1                54                1.95 (1.45--2.62)   1.95 (1.45--2.62)             0.795                    \-     \-
  Urinary system           1                40                1.14 (0.22--5.95)   1.14 (0.22--5.95)             \-                       \-     \-
  PC                       1                40                1.14 (0.22--5.95)   1.14 (0.22--5.95)             0.530                    \-     \-
  Analysis method                                                                                                                               
  Multivariable analysis   14               1154              1.80 (1.55--2.09)   1.80 (1.55--2.09)             \-                       0.0    0.722
  Univariable analysis     5                433               1.98 (1.55--2.55)   1.98 (1.55--2.55)             0.913                    0.0    0.956
  Sample size                                                                                                                                   
  Size ≥ 90                8                987               1.68 (1.41--2.00)   1.68 (1.41--2.00)             \-                       0.0    0.639
  Size \< 90               11               600               2.07 (1.71--2.50)   2.07 (1.71--2.50)             0.538                    0.0    0.979
  Quality scores                                                                                                                                
  Score ≥ 75               8                637               1.98 (1.58--2.48)   1.98 (1.58--2.48)             \-                       0.0    0.576
  Score \< 75              11               950               1.79 (1.53--2.09)   1.79 (1.53--2.09)             0.296                    0.0    0.921

Abbreviations: ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; NSCLC, non-small cell lung carcinoma; CRC, colorectal cancer; PC, prostate cancer; HCC, hepatocellular cancer; EOC, epithelial ovarian cancer; EC, endometrial cancer; PAC, pancreatic cancer; BC, breast cancer.

Publication bias evaluated by funnel plot and Egger\'s test indicated that there was evident asymmetry in this meta-analysis (p~Egger's~ = 0.006, Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). And publication bias of subgroup showed small-studies effects existed in large tumor sample size (p~Egger's~ = 0.001), high quality score (p~Egger's~ \< 0.001) and multivariate analysis subgroup (p~Egger's~ \< 0.001) in ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). However, sensitivity analysis by removing each research in turn showed the residual pooled HRs of OS were not impacted dramatically in Figure [2D](#F2){ref-type="fig"}.

Correlation between UCA1 level and clinical characteristics in patients with cancer {#s2_3}
-----------------------------------------------------------------------------------

In the clinicopathological studies, 16 researches consisting of 1291 tumor samples with a correlation between clinicopathological features and UCA1 expression were retrieved in OR analysis. Clinical stage, lymph node metastasis, distant metastasis and tumor size data were collected to analyze. UCA1 expression was significantly different in these clinicopathological factors ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). We found high UCA1 expression was associated with high grade cancer (pooled OR = 2.74, 95% CI 2.04--3.70, *p* \< 0.001), positive lymphatic metastasis (pooled OR = 2.43, 95% CI 1.72--3.41, *p* \< 0.001), and distant metastasis (pooled OR = 2.10, 95% CI 1.13--3.89, *p* \< 0.001) in Table [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}.

###### The subgroup and meta-regression analysis of the association and heterogeneity between high UCA1 expression and clinical stage

  Subgroup analysis             No. of studies   No. of patients   Pool OR (95% CI)    Meta-regression (*p* value)   Heterogeneity (random)          
  ----------------------------- ---------------- ----------------- ------------------- ----------------------------- ------------------------ ------ -------
  ORs of tumor stage subgroup   16               1291              2.63 (2.07--3.33)   2.74 (2.04--3.70)             \-                       30.8   0.116
  Cancer type                                                                                                                                        
  Digestive system              11               909               2.45 (1.86--3.24)   2.61 (1.74--3.91)             \-                       47.4   0.04
  GC                            2                149               3.32 (1.66--6.66)   4.18 (1.10--16.0)             0.855                    61.2   0.109
  CRC                           4                304               2.23 (1.38--3.60)   2.38 (1.18--4.80)             0.616                    49.5   0.114
  HCC                           2                158               2.78 (1.46--5.30)   2.53 (0.56--11.4)             0.702                    79.9   0.026
  PAC                           2                208               1.68 (0.91--3.09)   1.97 (0.66--5.89)             0.569                    54.2   0.140
  ESCC                          1                90                3.64 (1.49--8.88)   3.64 (1.49--8.88)             0.851                    \-     \-
  Respiratory system            2                172               3.74 (1.82--7.70)   3.71 (1.79--7.69)             \-                       0.0    0.368
  NSCLC                         2                172               3.74 (1.82--7.70)   3.71 (1.79--7.69)             0.869                    0.0    0.368
  Reproductive system           3                210               2.86 (1.60--5.14)   2.88 (1.60--5.17)             \-                       0.0    0.730
  EOC                           2                168               2.66 (1.42--5.00)   2.66 (1.42--5.00)             0.704                    0.0    0.648
  EC                            1                42                4.64 (0.98--22.0)   4.64 (0.98--22.0)             \-                       \-     \-
  Sample size                                                                                                                                        
  Size ≥ 90                     7                745               2.50 (1.84--3.40)   2.53 (1.80--3.55)             \-                       15.7   0.310
  Size \< 90                    9                546               2.83 (1.94--4.12)   3.12 (1.84--5.29)             0.761                    44.2   0.074
  Quality scores                                                                                                                                     
  Score ≥ 75                    7                560               2.79 (1.94--4.00)   3.07 (1.89--5.00)             \-                       37.8   0.141
  Score \< 75                   9                731               2.51 (1.83--3.45)   2.56 (1.72--3.82)             0.768                    32.8   0.156

Abbreviations: ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; NSCLC, non-small cell lung carcinoma; CRC, colorectal cancer; HCC, hepatocellular cancer; EOC, epithelial ovarian cancer; EC, endometrial cancer; PAC, pancreatic cancer.

###### The subgroup and meta-regression analysis of the association and heterogeneity between high UCA1 expression and tumor size

  Subgroup analysis            No. of studies   No. of patients   Pool OR (95% CI)    Meta-regression (*p* value)   Heterogeneity (random)          
  ---------------------------- ---------------- ----------------- ------------------- ----------------------------- ------------------------ ------ -------
  ORs of tumor size subgroup   13               1090              1.47 (1.15--1.87)   1.45 (0.99--2.14)             \-                       57.0   0.006
  Cancer type                                                                                                                                       
  Digestive system             9                762               1.41 (1.06--1.88)   1.42 (0.66--2.37)             \-                       64.6   0.004
  GC                           2                149               0.71 (0.37--1.35)   1.01 (0.17--6.04)             0.603                    81.5   0.02
  CRC                          3                250               1.89 (1.11--3.22)   1.81 (0.67--4.90)             0.822                    69.5   0.038
  HCC                          2                155               1.57 (0.83--2.96)   1.47 (0.55--3.93)             0.667                    55.2   0.135
  PAC                          2                208               1.58 (0.92--2.73)   1.49 (0.60--3.69)             \-                       61.3   0.108
  Respiratory system           2                172               1.98 (1.04--3.76)   1.99 (1.04--3.78)             \-                       0.0    0.350
  NSCLC                        2                172               1.98 (1.04--3.76)   1.99 (1.04--3.78)             0.938                    0.0    0.350
  Reproductive system          2                156               1.36 (0.73--2.54)   1.19 (0.34--4.18)             \-                       71.6   0.060
  EOC                          2                156               1.36 (0.73--2.54)   1.19 (0.34--4.18)             0.623                    71.6   0.060
  Sample size                                                                                                                                       
  Size ≥ 90                    6                643               1.76 (1.28--2.41)   1.83 (1.02--3.28)             \-                       69.1   0.006
  Size \< 90                   7                447               1.13 (0.77--1.66)   1.13 (0.71--1.80)             0.575                    29.5   0.203
  Quality scores                                                                                                                                    
  Score ≥ 75                   6                470               1.07 (0.75--1.54)   1.08 (0.58--2.00)             \-                       61.2   0.024
  Score \< 75                  7                620               1.92 (1.38--2.68)   1.88 (1.23--2.89)             0.599                    37.9   0.140

Abbreviations: GC, gastric cancer; NSCLC, non-small cell lung carcinoma; CRC, colorectal cancer; HCC, hepatocellular cancer; EOC, epithelial ovarian cancer; PAC, pancreatic cancer.

###### The subgroup and meta-regression analysis of the association and heterogeneity between high UCA1 expression and lymph node metastasis

  Subgroup analysis                       No. of studies   No. of patients   Pool OR (95% CI)    Meta-regression (*p* value)   Heterogeneity (random)          
  --------------------------------------- ---------------- ----------------- ------------------- ----------------------------- ------------------------ ------ -------
  ORs of lymph node metastasis subgroup   15               1229              2.26 (1.78--2.86)   2.43 (1.72--3.41)             \-                       47.1   0.023
  Cancer type                                                                                                                                                  
  Digestive system                        10               849               2.05 (1.55--2.71)   2.17 (1.42--3.31)             \-                       52.1   0.027
  GC                                      2                149               1.36 (0.71--2.60)   1.99 (0.32--12.5)             0.290                    81.0   0.022
  CRC                                     4                304               2.07 (1.28--3.34)   2.07 (1.25--3.43)             0.290                    5.6    0.365
  HCC                                     1                98                5.46 (2.26--13.2)   5.46 (2.26--13.2)             0.970                    \-     \-
  PAC                                     2                208               1.48 (0.85--2.57)   1.46 (0.78--2.73)             0.235                    19.6   0.265
  ESCC                                    1                90                3.57 (1.48--8.74)   3.57 (1.48--8.74)             0.595                    \-     \-
  Respiratory system                      2                172               2.23 (1.17--4.25)   2.54 (0.70--9.23)             \-                       71.1   0.063
  NSCLC                                   2                172               2.23 (1.17--4.25)   2.54 (0.70--9.23)             0.372                    71.1   0.063
  Reproductive system                     3                208               3.65 (1.96--6.81)   3.70 (1.98--6.91)             \-                       0.0    0.509
  EOC                                     2                163               3.16 (1.59--6.27)   3.16 (1.59--6.27)             0.495                    0.0    0.684
  EC                                      1                45                7.84 (1.77--34.8)   7.84 (1.77--34.8)             0.961                    \-     \-
  Sample size                                                                                                                                                  
  Size ≥ 90                               7                740               2.09 (1.55--2.83)   2.14 (1.36--3.53)             \-                       52.5   0.049
  Size \< 90                              8                489               2.55 (1.74--3.73)   2.89 (1.67--5.00)             0.589                    46.8   0.068
  Quality scores                                                                                                                                               
  Score ≥ 75                              7                560               2.02 (1.43--2.84)   2.27 (1.29--4.00)             \-                       58.9   0.024
  Score \< 75                             8                669               2.51 (1.81--3.49)   2.60 (1.69--4.00)             0.597                    36.9   0.135

Abbreviations: ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; NSCLC, non-small cell lung carcinoma; CRC, colorectal cancer; HCC, hepatocellular cancer; EOC, epithelial ovarian cancer; EC, endometrial cancer; PAC, pancreatic cancer.

###### The subgroup and meta-regression analysis of the association and heterogeneity between high UCA1 expression and distant metastasis

  Subgroup analysis                    No. of studies   No. of patients   Pool OR (95% CI)    Meta-regression (*p* value)   Heterogeneity (random)          
  ------------------------------------ ---------------- ----------------- ------------------- ----------------------------- ------------------------ ------ -------
  ORs of distant metastasis subgroup   8                687               2.05 (1.42--2.96)   2.10 (1.13--3.89)             \-                       56.5   0.024
  Cancer type                                                                                                                                               
  Digestive system                     7                642               1.89 (1.29--2.78)   1.84 (0.97--3.49)             \-                       55.7   0.035
  GC                                   1                112               6.25 (1.48--26.4)   6.25 (1.48--26.4)             \-                       \-     \-
  CRC                                  3                224               2.08 (0.97--4.48)   1.98 (0.85--4.59)             \-                       8.0    0.337
  HCC                                  1                98                5.46 (2.26--13.2)   5.46 (2.26--13.2)             \-                       \-     \-
  PAC                                  2                208               1.66 (0.86--3.21)   1.66 (0.85--3.22)             \-                       0.0    0.446
  Reproductive system                  1                45                6.25 (1.48--26.4)   6.25 (1.48--26.4)             \-                       \-     \-
  EC                                   1                45                6.25 (1.48--26.4)   6.25 (1.48--26.4)             \-                       \-     \-
  Sample size                                                                                                                                               
  Size ≥ 90                            4                428               1.98 (1.28--3.07)   1.96 (0.81--4.75)             \-                       71.9   0.014
  Size \< 90                           4                259               2.22 (1.12--4.42)   2.34 (0.86--6.37)             0.752                    44.3   0.143
  Quality scores                                                                                                                                            
  Score ≥ 75                           3                320               1.20 (0.71--2.10)   1.14 (0.55--2.36)             \-                       38.4   0.197
  Score \< 75                          11               367               3.43 (2.01--5.85)   3.38 (1.69--6.74)             0.104                    31.4   0.212

Abbreviations: GC, gastric cancer; CRC, colorectal cancer; HCC, hepatocellular cancer; EC, endometrial cancer; PAC, pancreatic cancer.

The subgroup analysis stratified by cancer type, sample size and quality score uncovered the resource of heterogeneity under the fixed effect model, random effect model and meta-regression analysis (Table [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}). There existed a significantly statistical heterogeneity across distant metastasis subgroup (I^2^ = 56.5%, p~H~ = 0.024) in 8 clinicopathological studies shown in Table [6](#T6){ref-type="table"}. In distant metastasis heterogeneity analysis, we detected a significant heterogeneity in large sample size (I^2^ = 71.9%, p~H~ = 0.014) subgroup. No evidence of statistical heterogeneity was detected in cancer type and lymphatic metastasis subgroup (I^2^ = 30.8%, p~H~ = 0.116 and I^2^ = 47.1%, p~H~ = 0.023, respectively). However, only CRC showed clinical significance and no obvious heterogeneity (pooled OR = 2.38, 95% CI 1.18--4.80, *p* \< 0.001, I^2^ = 49.5%, p~H~ = 0.114) by stratification analysis of cancer type. In subsequent stratification analysis of lymphatic metastasis, there was no evidence of significant heterogeneity in CRC (pooled OR = 2.07, 95% CI 1.25--3.43, *p* = 0.003, I^2^ = 5.6%, p~H~ = 0.365) and EOC (pooled OR = 3.16, 95% CI 1.59--6.27, p *p* \< 0.001, I^2^ = 0.0%, p~H~ = 0.684) subgroup.

A Egger\'s linear regression test was conducted to evaluate publication bias of these clinicopathological covariates. The result showed no publication bias existed between tumor size and distant metastasis subgroup in ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}) (p~Egger's~ = 0.622 and p~Egger's~ = 0.653, respectively) and no asymmetry among 4 subgroups in the sensitivity analysis ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

Cancer attacks all humankinds as a major cause of morbidity and mortality in worldwide regions with approximately 14.1 million new cancer cases and 8.2 million cancer-related deaths in 2012 \[[@R28]\]. Despite significant advances in cancer treatment, an unexpected long-term overall survival is still an important public health challenge. Therefore, novel strategies for detection of diagnostic and prognostic biomarkers and identification of potential therapeutic targets have attracted increasing interest.

The emerging next generation sequencing technology and large-scale of transcriptome mapping have provided an opportunity to facilitate to understand genome information and identify over 90% non-coding RNAs regarded as "transcriptional noise" before. Continuing advances in these new technologies indicate the vital and complex functions of lncRNAs in gene regulation. With these updated views, the central dogma may be rewritten \[[@R6], [@R7]\]. Recent numerous studies have confirmed that lncRNAs as oncogenes or tumor suppressors play important regulatory roles in biological progress of a broad range of cancers or other human diseases. Substantial progress of lncRNAs demonstrate they may act as molecular scaffolds, sponges or co-activators by interaction with DNA, RNA or proteins in cancer nosogenesis \[[@R1], [@R5], [@R6]\]. Currently, a growing body of evidence revealed aberrant UCA1 as an oncogene in various malignancies \[[@R11]--[@R13], [@R15]--[@R27]\]. Intensive researches have showed overexpression of UCA1 can promote the progression of proliferation, invasion, migration, metastasis, chemoresistance in a variety of cancers \[[@R10]\]. Moreover, the dysregulation of UCA1 was also found in acute myocardial infarction, kidney damage and neurodegenerative diseases \[[@R10]\]. In cancer, the binding between UCA1 promoter core region and transcription factors or complex (C/EBPα, Ets-2, TAZ/YAP/TEAD and SMAD2/3) can enhance UCA1 promoter activity and gene expression \[[@R29], [@R30]\]. The upregulation of UCA1 is responsible for tumor cell proliferation by suppressing G0/G1 cell cycle arrest and apoptosis. Furthermore, increased UCA1 promotes cancer invasion and metastasis by activation of metastasis genes including MMP14, FGFR1/ERK and ZEB1/2-FSCN1, and enhances chemoresistance by a set of anti-apoptosis genes and signaling pathways (PARP/BCL-2, CREB1/BCL-2/RAB22A, AKT/mTOR and Wnt signaling pathway) \[[@R11], [@R13], [@R19], [@R21], [@R24], [@R31]--[@R33]\]. UCA1 is also a key molecular sponge or competing endogenous RNA (ceRNA) for miR-1, miR-204--5p, miR-193a-3p, miR-145 and miR-216 \[[@R13], [@R19], [@R26], [@R32], [@R34]\]. Simultaneously, UCA1 is associated with clinical parameters and prognosis of cancer patients and may be a potential diagnosis biomarker in gastric cancer, hepatocellular cancer and bladder cancer \[[@R15], [@R22], [@R23], [@R35]\].

Here, we performed this meta-analysis to explore the correlation between high expression of UCA1 and clinicopathological characteristics and evaluate the prognosis role of UCA1 for cancer patients. All of these results above suggest that high UCA1 expression may be regarded as an unfavorable predictor in different cancers (pooled HR = 1.85, 95% CI 1.62--2.10, *p* \< 0.001). Meanwhile, the pooled data of eligible studies also indicated that high UCA1 expression was significant correlated with poor grade cancer (pooled OR = 2.74, 95% CI 2.04--3.70, *p* \< 0.001, I^2^ = 49.5%, p~H~ = 0.1) and positive lymph node metastasis (pooled OR = 2.43, 95% CI 1.72--3.41, *p* \< 0.001).

Otherwise, it should be acknowledged that several limitations existed in this current meta-analysis. First, almost all available studies were performed in China. The prognostic role of UCA1 should be taken cautiously in other regions and ethnicities. Second, inadequate data from some types of cancer and subgroup analysis in HRs and ORs may be the origin of heterogeneity. Third, the inconsistent cut-off value of UCA1 expression due to different methods and criteria may result in some heterogeneity. Finally, included papers were only English and most of which reported positive results, which may generate publication bias. Thus, the predictive significance of evaluated UCA1 in poor prognosis of patients with cancer might be overestimated to some extent. In addition, recent publications demonstrated a friendly and open user server by computational approaches will facilitate novel technologies and findings accessible to the public and enhance their impacts \[[@R36]--[@R38]\]. Hence, we appeal to establish a web-server of raw and integrated data for further analysis in drug design and in-depth investigation, such as UCA1. In conclusion, the present analysis showed that overexpression of UCA1 might predict a poor prognosis in various types of malignancies, especially in Chinese population and was associated with poor cancer stage and positive lymphatic metastasis. Therefore, UCA1 may serve as an effective biomarker to predict prognosis and tumor progression of patients with cancer. Nevertheless, more large-scale and well-designed studies are required to update the findings of this analysis.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and study selection criteria {#s4_1}
--------------------------------------------

Systematic literature searches were conducted in PubMed, Embase, Cochrane Library and Web of Science databases (up to January 17, 2017) with the following searching strategy: "UCA1" OR "UCA 1" OR "UCA-1" OR "urothelial cancer associated 1" OR "urothelial cancer associated-1" OR "CUDR" OR "LINC00178" OR "NCRNA00178" OR "onco-lncRNA-36" OR "ENSG00000214049") AND ("cancer" OR "tumor" OR "tumour" OR "carcinoma" OR "neoplasm" OR "adenoma" OR "sarcoma"). We manually searched retrieved references for potentially missing literatures. The cited articles were excluded from duplicated firstly, then titles and abstracts were carefully scanned to eliminate irrelevant studies. Finally, we prudently reviewed full texts of potential retrieved studies. Studies were available upon the eligibility criteria: (1) showed the relationship between the dichotomous UCA1 levels and prognosis and clinicopathological characteristics of patients with any type of cancer; (2) calculated HRs and 95% CIs for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS); (3) were published in English. Duplicated, non-dichotomous expression of UCA1 or non-English articles, absence of key survival outcome such as HRs, 95% CIs or Kaplan-Meier survival curve, reviews, letters, laboratory studies of non-human research or comments were omitted.

Data extraction {#s4_2}
---------------

Eligible data were deliberatively judged and double checked from available studies based on criteria of inclusion and exclusion. To each study, we carefully extracted the following information: first author, journal, year of publication, country, ethnicity of the study population, type of specimen, carcinoma type, number of patients, detection method, cut-off value, follow-up, quality score and HR and 95% CI for OS, PFS, or DFS. Quality assessment of the available studies was performed upon the REMARK guideline \[[@R39]\]. HR, as a dominant indicator of interest, was respectively extracted from multivariable analysis, univariate analysis, additional information of first authors' e-mails and estimated from graphical survival plots by Engauge Digitizer 4.1 software as described previously, if only Kaplan-Meier curve existed \[[@R40], [@R41]\]. Clinical parameters with dichotomous UCA1 levels also were retrieved such as clinical stage (TNM stage), tumor size, lymphatic and distant metastasis.

Statistical analysis {#s4_3}
--------------------

All analysis was conducted with STATA software version 12.0 (STATA Corporation, College Station, TX, USA). Odds Ratios (ORs) were performed to analyze the association of UCA1 expression with clinical stage, tumor size, lymphatic and distant metastasis and HRs with corresponding 95% CIs were utilized to estimate the relationship strength between UCA1 expression and patients' prognosis. If the HRs were not directly reported in original articles, we calculated the essential data upon the previously reported methods \[[@R40]\]. The pooled HRs were estimated using a fixed effect model (Mantel-Haenszel) in the absence of heterogeneity, if heterogeneity was observed applying a random effect model (DerSimoian-Laird) and meta-regression analysis \[[@R41], [@R42]\]. The heterogeneity tests of combined HRs and ORs were carried out by Cochran\'s *Q* test and Higgins I-squared statistic (P~H~ \< 0.1 and I^2^ \> 50%). To further explore the potential heterogeneity factors and outcome stability in studies, a subgroup analysis and a sensitivity analysis were utilized respectively in the meta-analysis. Publication bias was evaluated by a funnel plot and Egger\'s linear regression test with a significant publication bias by *P* \< 0.05.
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